Materiały źródłowe

• #1 Diagnostic Workup for Advanced Forms of Mastocytosis – TMS – The Mast Cell Disease Society, IncAccessibilityIncrease TextDecrease TextGrayscaleHigh ContrastNegative ContrastLight BackgroundLinks UnderlineReadable FontReset

  https://tmsforacure.org/expert-information/diagnostic-workup-advanced-forms-mastocytosis/

  Mastocytosis denotes a heterogeneous group of disorders characterized by abnormal growth and accumulation of mast cells (MCs) that has a variable prognosis and course of disease. […] The diagnosis of mastocytosis is established in a stepwise approach, using WHO major and minor criteria (with one major and one minor or at least three minor criteria having to be fulfilled). […] The major criterion is multifocal mast cell infiltration in the bone marrow (BM) or in an extracutaneous organ, as assessed by histology. […] Minor SM criteria relate to the morphology of mast cells (histology and/or cytology), their cell surface markers (aberrant expression of CD2 and/or CD25), molecular findings (KIT mutation at codon 816), and serum tryptase level (>20 ng/ml). […] To diagnose an advanced form of mastocytosis, the presence of B-findings, C-findings, or an AHN is of importance.

• #2 Mastocytosis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3863935/

  Mastocytosis is a disorder of abnormal mast cell proliferation with clinical features that include flushing, pruritus, abdominal pain, diarrhea, hypotension, syncope and musculoskeletal pain. […] This article encapsulates the etiology and pathogenesis of mastocytosis with an overview of the clinical features and the approach to diagnosis, evaluation and therapy in adults and pediatric patients. […] Mastocytosis is diagnosed on the basis of history, clinical manifestations, histopathology and laboratory evaluation. It is then classified as to variant based on WHO criteria. […] The diagnosis of cutaneous mastocytosis based on macroscopic appearance is confirmed with a lesional skin biopsy demonstrating characteristic skin histopathology. […] The current approach to the work-up of a patient for systemic mastocytosis consists of a medical evaluation including a bone marrow biopsy and aspirate, a serum tryptase level, and an analysis for an activating mutation in KIT, preferably on bone marrow mononuclear cells.

• #3 Systemic mastocytosis – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/systemic-mastocytosis/diagnosis-treatment/drc-20450478

  To diagnose systemic mastocytosis, your doctor will likely start by reviewing your symptoms and discussing your medical history, including medications you’ve taken. He or she can then order tests that look for high levels of mast cells or the substances they release. Evaluation of organs affected by the condition also may be done. […] Tests may include: Blood or urine tests, Bone marrow biopsy, Skin biopsy, Imaging tests such as an X-ray, ultrasound, bone scan and CT scan, Biopsy of organs affected by the disease, such as the liver, Genetic testing. […] Your doctor regularly monitors the status of your condition using blood and urine samples. You may be able to use a special home kit to collect blood and urine samples while you’re experiencing symptoms, which gives your doctor a better picture of how systemic mastocytosis affects your body. Regular bone density measurements can monitor you for problems such as osteoporosis. […] After getting detailed information about the symptoms and your family’s medical history, your doctor may order tests to help with diagnosis and treatment planning.

• #4 Systemic Mastocytosis

  https://www.aaaai.org/conditions-treatments/related-conditions/systemic-mastocytosis

  Mastocytosis is diagnosed by sampling the tissues where there is an abundance by using biopsies, measuring mast cell mediators in blood and urine, blood counts, liver function studies and genetic tests. […] Thus, in adults it is important to look for possible systemic mastocytosis using biopsies of organs in addition to the skin. A bone marrow biopsy is typically used because mast cell precursors originate in the bone marrow before migrating to other organs to mature and are more abundant there. […] The diagnosis of systemic mastocytosis is determined by criteria established by the World Health Organization consensus group and requires meeting the major criterion plus one minor criterion or, alternatively, three of the minor criteria. […] The subgroups are listed here, with indolent systemic mastocytosis being the most frequent, and the other subgroups in order of increasing aggressiveness: Indolent systemic mastocytosis Smoldering systemic mastocytosis Aggressive systemic mastocytosis Systemic mastocytosis with an associated hematologic neoplasm Mast cell leukemia.

• #5 Diagnostic Workup for Advanced Forms of Mastocytosis – TMS – The Mast Cell Disease Society, IncAccessibilityIncrease TextDecrease TextGrayscaleHigh ContrastNegative ContrastLight BackgroundLinks UnderlineReadable FontReset

  https://tmsforacure.org/expert-information/diagnostic-workup-advanced-forms-mastocytosis/

  Mastocytosis denotes a heterogeneous group of disorders characterized by abnormal growth and accumulation of mast cells (MCs) that has a variable prognosis and course of disease. […] The diagnosis of mastocytosis is established in a stepwise approach, using WHO major and minor criteria (with one major and one minor or at least three minor criteria having to be fulfilled). […] The major criterion is multifocal mast cell infiltration in the bone marrow (BM) or in an extracutaneous organ, as assessed by histology. […] Minor SM criteria relate to the morphology of mast cells (histology and/or cytology), their cell surface markers (aberrant expression of CD2 and/or CD25), molecular findings (KIT mutation at codon 816), and serum tryptase level (>20 ng/ml). […] To diagnose an advanced form of mastocytosis, the presence of B-findings, C-findings, or an AHN is of importance.

• #6 Diagnostic Workup for Advanced Forms of Mastocytosis – TMS – The Mast Cell Disease Society, IncAccessibilityIncrease TextDecrease TextGrayscaleHigh ContrastNegative ContrastLight BackgroundLinks UnderlineReadable FontReset

  https://tmsforacure.org/expert-information/diagnostic-workup-advanced-forms-mastocytosis/

  Mastocytosis denotes a heterogeneous group of disorders characterized by abnormal growth and accumulation of mast cells (MCs) that has a variable prognosis and course of disease. […] The diagnosis of mastocytosis is established in a stepwise approach, using WHO major and minor criteria (with one major and one minor or at least three minor criteria having to be fulfilled). […] The major criterion is multifocal mast cell infiltration in the bone marrow (BM) or in an extracutaneous organ, as assessed by histology. […] Minor SM criteria relate to the morphology of mast cells (histology and/or cytology), their cell surface markers (aberrant expression of CD2 and/or CD25), molecular findings (KIT mutation at codon 816), and serum tryptase level (>20 ng/ml). […] To diagnose an advanced form of mastocytosis, the presence of B-findings, C-findings, or an AHN is of importance.

• #7 Mastocytosis – Australasian Society of Clinical Immunology and Allergy (ASCIA)

  https://www.allergy.org.au/patients/allergy-testing/mastocytosis

  Mastocytosis occurs when the body produces too many mast cells. These cells can continue growing and tend to be overly sensitive to activation and releasing mediators. If the cells build up (accumulate) in organ tissues, this can result in symptoms that affect multiple organ systems. […] Mastocytosis is an abnormal accumulation of mast cells in one or more organ systems. There are three types: […] Systemic mastocytosis (SM) is usually diagnosed by a bone marrow (BM) biopsy. Tryptase levels when measured on a blood test are almost always high in people with SM. […] Diagnosis of MCAS usually involves measurement of mast cell mediators, which increase during the episode. For example, a tryptase level measured on a blood test may be high during an episode, and then return to lower levels after the episode.

• #8 Diagnostic Workup for Advanced Forms of Mastocytosis – TMS – The Mast Cell Disease Society, IncAccessibilityIncrease TextDecrease TextGrayscaleHigh ContrastNegative ContrastLight BackgroundLinks UnderlineReadable FontReset

  https://tmsforacure.org/expert-information/diagnostic-workup-advanced-forms-mastocytosis/

  Mastocytosis denotes a heterogeneous group of disorders characterized by abnormal growth and accumulation of mast cells (MCs) that has a variable prognosis and course of disease. […] The diagnosis of mastocytosis is established in a stepwise approach, using WHO major and minor criteria (with one major and one minor or at least three minor criteria having to be fulfilled). […] The major criterion is multifocal mast cell infiltration in the bone marrow (BM) or in an extracutaneous organ, as assessed by histology. […] Minor SM criteria relate to the morphology of mast cells (histology and/or cytology), their cell surface markers (aberrant expression of CD2 and/or CD25), molecular findings (KIT mutation at codon 816), and serum tryptase level (>20 ng/ml). […] To diagnose an advanced form of mastocytosis, the presence of B-findings, C-findings, or an AHN is of importance.

• #9 Diagnostic Workup for Advanced Forms of Mastocytosis – TMS – The Mast Cell Disease Society, IncAccessibilityIncrease TextDecrease TextGrayscaleHigh ContrastNegative ContrastLight BackgroundLinks UnderlineReadable FontReset

  https://tmsforacure.org/expert-information/diagnostic-workup-advanced-forms-mastocytosis/

  Mastocytosis denotes a heterogeneous group of disorders characterized by abnormal growth and accumulation of mast cells (MCs) that has a variable prognosis and course of disease. […] The diagnosis of mastocytosis is established in a stepwise approach, using WHO major and minor criteria (with one major and one minor or at least three minor criteria having to be fulfilled). […] The major criterion is multifocal mast cell infiltration in the bone marrow (BM) or in an extracutaneous organ, as assessed by histology. […] Minor SM criteria relate to the morphology of mast cells (histology and/or cytology), their cell surface markers (aberrant expression of CD2 and/or CD25), molecular findings (KIT mutation at codon 816), and serum tryptase level (>20 ng/ml). […] To diagnose an advanced form of mastocytosis, the presence of B-findings, C-findings, or an AHN is of importance.

• #10 Diagnostic Workup for Advanced Forms of Mastocytosis – TMS – The Mast Cell Disease Society, IncAccessibilityIncrease TextDecrease TextGrayscaleHigh ContrastNegative ContrastLight BackgroundLinks UnderlineReadable FontReset

  https://tmsforacure.org/expert-information/diagnostic-workup-advanced-forms-mastocytosis/

  Mastocytosis denotes a heterogeneous group of disorders characterized by abnormal growth and accumulation of mast cells (MCs) that has a variable prognosis and course of disease. […] The diagnosis of mastocytosis is established in a stepwise approach, using WHO major and minor criteria (with one major and one minor or at least three minor criteria having to be fulfilled). […] The major criterion is multifocal mast cell infiltration in the bone marrow (BM) or in an extracutaneous organ, as assessed by histology. […] Minor SM criteria relate to the morphology of mast cells (histology and/or cytology), their cell surface markers (aberrant expression of CD2 and/or CD25), molecular findings (KIT mutation at codon 816), and serum tryptase level (>20 ng/ml). […] To diagnose an advanced form of mastocytosis, the presence of B-findings, C-findings, or an AHN is of importance.

• #11 Diagnostic Workup for Advanced Forms of Mastocytosis – TMS – The Mast Cell Disease Society, IncAccessibilityIncrease TextDecrease TextGrayscaleHigh ContrastNegative ContrastLight BackgroundLinks UnderlineReadable FontReset

  https://tmsforacure.org/expert-information/diagnostic-workup-advanced-forms-mastocytosis/

  Mastocytosis denotes a heterogeneous group of disorders characterized by abnormal growth and accumulation of mast cells (MCs) that has a variable prognosis and course of disease. […] The diagnosis of mastocytosis is established in a stepwise approach, using WHO major and minor criteria (with one major and one minor or at least three minor criteria having to be fulfilled). […] The major criterion is multifocal mast cell infiltration in the bone marrow (BM) or in an extracutaneous organ, as assessed by histology. […] Minor SM criteria relate to the morphology of mast cells (histology and/or cytology), their cell surface markers (aberrant expression of CD2 and/or CD25), molecular findings (KIT mutation at codon 816), and serum tryptase level (>20 ng/ml). […] To diagnose an advanced form of mastocytosis, the presence of B-findings, C-findings, or an AHN is of importance.

• #12

  https://www.nhs.uk/conditions/mastocytosis/

  A physical examination of the skin is the first stage in diagnosing cutaneous mastocytosis. […] It’s usually possible to confirm a diagnosis by carrying out a biopsy, where a small skin sample is taken and checked for mast cells. […] A diagnosis of systemic mastocytosis is usually made by finding typical changes on a bone marrow biopsy.

• #13

  https://www.nhs.uk/conditions/mastocytosis/

  A physical examination of the skin is the first stage in diagnosing cutaneous mastocytosis. […] It’s usually possible to confirm a diagnosis by carrying out a biopsy, where a small skin sample is taken and checked for mast cells. […] A diagnosis of systemic mastocytosis is usually made by finding typical changes on a bone marrow biopsy.

• #14 Mastocytosis Workup: Laboratory Studies, Imaging Studies, Other Tests

  https://emedicine.medscape.com/article/1057932-workup

  In many patients, urticaria pigmentosa (UP) can be diagnosed when history and physical examination findings reveal the characteristic lesions that demonstrate the Darier sign. Usually, a skin biopsy is a necessary confirmatory test, typically through a 3- or 4-mm punch biopsy. It may be helpful to complete two biopsies, one of the suspected lesion and the other of unaffected skin, in order to compare the presence of mast cells. For aid in the diagnosis, the following stains are recommended to be completed with biopsy: hematoxylin, eosin, toluidine blue, Giemsa, and monoclonal antibodies to tryptase, CD117 and KIT. […] CBC count: In systemic mastocytosis, CBC counts may reveal anemia, thrombocytopenia, thrombocytosis, leukocytosis, and eosinophilia. […] Total tryptase level: Tryptase is a marker of mast cell degranulation released in parallel with histamine. Total tryptase levels in plasma correlate with the density of mast cells in urticaria pigmentosa lesions in adults with systemic mastocytosis. Patients with only cutaneous mastocytosis typically have normal levels of total tryptase. Total tryptase values are recommended by the WHO as a minor criterion for use in the diagnostic evaluation of systemic mastocytosis.

• #15 Mastocytosis Workup: Laboratory Studies, Imaging Studies, Other Tests

  https://emedicine.medscape.com/article/1057932-workup

  In many patients, urticaria pigmentosa (UP) can be diagnosed when history and physical examination findings reveal the characteristic lesions that demonstrate the Darier sign. Usually, a skin biopsy is a necessary confirmatory test, typically through a 3- or 4-mm punch biopsy. It may be helpful to complete two biopsies, one of the suspected lesion and the other of unaffected skin, in order to compare the presence of mast cells. For aid in the diagnosis, the following stains are recommended to be completed with biopsy: hematoxylin, eosin, toluidine blue, Giemsa, and monoclonal antibodies to tryptase, CD117 and KIT. […] CBC count: In systemic mastocytosis, CBC counts may reveal anemia, thrombocytopenia, thrombocytosis, leukocytosis, and eosinophilia. […] Total tryptase level: Tryptase is a marker of mast cell degranulation released in parallel with histamine. Total tryptase levels in plasma correlate with the density of mast cells in urticaria pigmentosa lesions in adults with systemic mastocytosis. Patients with only cutaneous mastocytosis typically have normal levels of total tryptase. Total tryptase values are recommended by the WHO as a minor criterion for use in the diagnostic evaluation of systemic mastocytosis.

• #16 Mastocytosis Workup: Laboratory Studies, Imaging Studies, Other Tests

  https://emedicine.medscape.com/article/1057932-workup

  In many patients, urticaria pigmentosa (UP) can be diagnosed when history and physical examination findings reveal the characteristic lesions that demonstrate the Darier sign. Usually, a skin biopsy is a necessary confirmatory test, typically through a 3- or 4-mm punch biopsy. It may be helpful to complete two biopsies, one of the suspected lesion and the other of unaffected skin, in order to compare the presence of mast cells. For aid in the diagnosis, the following stains are recommended to be completed with biopsy: hematoxylin, eosin, toluidine blue, Giemsa, and monoclonal antibodies to tryptase, CD117 and KIT. […] CBC count: In systemic mastocytosis, CBC counts may reveal anemia, thrombocytopenia, thrombocytosis, leukocytosis, and eosinophilia. […] Total tryptase level: Tryptase is a marker of mast cell degranulation released in parallel with histamine. Total tryptase levels in plasma correlate with the density of mast cells in urticaria pigmentosa lesions in adults with systemic mastocytosis. Patients with only cutaneous mastocytosis typically have normal levels of total tryptase. Total tryptase values are recommended by the WHO as a minor criterion for use in the diagnostic evaluation of systemic mastocytosis.

• #17 Challenges in the Diagnosis of Cutaneous Mastocytosis

  https://www.mdpi.com/2075-4418/14/2/161

  Conclusions: Whereas in typical cases the diagnosis of CM may be uncomplicated, less typical manifestations may require specific investigations for making the diagnosis and predicting its course. […] For dermatologists, typical skin lesions together with a clearly positive Darier’s sign and clinical exclusion of differential diagnoses are sufficient to confirm the diagnosis of CM. […] If CM is atypical, Darier’s sign is negative, or other dermatological diseases are included in the differential diagnosis, dermatohistopathology is required for diagnosis. […] Detection of a KIT mutation at codon 816 in skin tissue is sometimes required as a specific and sensitive method for making the diagnosis of CM. […] The course of mastocytosis in adults is usually chronic. […] In adults with CM and cutaneous or indolent systemic disease, progression into an aggressive advanced form of disease is seldom. […] The nomenclature used for various forms of mastocytosis is complex and requires knowledge of the definitions, such as the use of “CM”, which is defined as a diagnosis only for patients without involvement of extracutaneous organs.

• #18 Mastocytosis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3863935/

  Mastocytosis is a disorder of abnormal mast cell proliferation with clinical features that include flushing, pruritus, abdominal pain, diarrhea, hypotension, syncope and musculoskeletal pain. […] This article encapsulates the etiology and pathogenesis of mastocytosis with an overview of the clinical features and the approach to diagnosis, evaluation and therapy in adults and pediatric patients. […] Mastocytosis is diagnosed on the basis of history, clinical manifestations, histopathology and laboratory evaluation. It is then classified as to variant based on WHO criteria. […] The diagnosis of cutaneous mastocytosis based on macroscopic appearance is confirmed with a lesional skin biopsy demonstrating characteristic skin histopathology. […] The current approach to the work-up of a patient for systemic mastocytosis consists of a medical evaluation including a bone marrow biopsy and aspirate, a serum tryptase level, and an analysis for an activating mutation in KIT, preferably on bone marrow mononuclear cells.

• #19 Mastocytosis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3863935/

  The diagnosis of systemic disease requires fulfilling the major criterion, consisting of multifocal dense mast cell aggregates, and one minor criterion; or three minor criteria. […] The diagnosis of mastocytosis should also be considered when a patient, primarily in the adult population, presents with one or more of the following: unexplained ulcer disease or malabsorption, radiographic or 99Tc bone scan abnormalities, hepatomegaly, splenomegaly, lymphadenopathy, peripheral blood abnormalities, venom anaphylaxis, or unexplained flushing or hypotension.

• #20 Diagnostic Workup for Advanced Forms of Mastocytosis – TMS – The Mast Cell Disease Society, IncAccessibilityIncrease TextDecrease TextGrayscaleHigh ContrastNegative ContrastLight BackgroundLinks UnderlineReadable FontReset

  https://tmsforacure.org/expert-information/diagnostic-workup-advanced-forms-mastocytosis/

  In patients with two or more B-findings the diagnosis of smoldering systemic mastocytosis (SSM) can be established. […] C-findings (one is enough to diagnose aggressive SM) are indicative of ASM or MCL. […] It is of particular importance that organ damage caused by MC infiltration only counts as an SM-related C-finding. […] In case of suspected AHN, further markers and criteria to classify the AHN according to WHO criteria have to be applied to fully diagnose both the SM component and the AHN component of the disease and to identify potential drug targets. […] Elevated serum tryptase is the key finding in patients with SM. […] Moreover, tryptase may serve as a surrogate marker to estimate the aggressiveness of the disease. […] Tryptase measurement is also of importance for the monitoring of SM.

• #21 Systemic Mastocytosis Workup: Approach Considerations, Laboratory Studies, Imaging Studies

  https://emedicine.medscape.com/article/203948-workup

  Blood studies used in the diagnosis of systemic mastocytosis include the following: […] The World Health Organization has established diagnostic and classification criteria for systemic mastocytosis. […] Total serum tryptase levels of 20 ng/mL or higher in a baseline serum sample that is associated with a ratio of total to beta-tryptase ratio greater than 20:1 is suggestive of systemic mastocytosis. […] However, a normal serum tryptase level does not exclude the diagnosis of systemic mastocytosis. […] Cytogenetic data indicate that about 20% of patients with systemic mastocytosis have an abnormal karyotype. […] Molecular testing for KIT D816V mutation is universally positive, whereas JAK2 V617F is rarely positive (4%). […] Bone marrow aspiration and biopsy is essential for the diagnosis of systemic mastocytosis.

• #22 Diagnostic Workup for Advanced Forms of Mastocytosis – TMS – The Mast Cell Disease Society, IncAccessibilityIncrease TextDecrease TextGrayscaleHigh ContrastNegative ContrastLight BackgroundLinks UnderlineReadable FontReset

  https://tmsforacure.org/expert-information/diagnostic-workup-advanced-forms-mastocytosis/

  Many patients with advanced SM present with abnormal peripheral blood counts. […] An abnormal blood count is also a key finding to detect an AHN and to diagnose SM-AHN. […] Although the presence of the major criterion for diagnosis of SM can be evaluated with a biopsy from any organ involved in disease other than skin (e.g., liver, gastrointestinal tract), bone marrow is the most common site. […] There are many pros of a bone marrow biopsy/aspirate, including providing information on an AHN, rendering differential diagnosis with other possible malignancies, and being easy and safe. […] The most important molecular marker to show monoclonality in SM is the KIT point mutation D816V that can be analyzed in the bone marrow and the peripheral blood. […] In the majority of patients with SM, neoplastic MCs harbor this mutation.

• #23 Mastocytosis Workup: Laboratory Studies, Imaging Studies, Other Tests

  https://emedicine.medscape.com/article/1057932-workup

  In many patients, urticaria pigmentosa (UP) can be diagnosed when history and physical examination findings reveal the characteristic lesions that demonstrate the Darier sign. Usually, a skin biopsy is a necessary confirmatory test, typically through a 3- or 4-mm punch biopsy. It may be helpful to complete two biopsies, one of the suspected lesion and the other of unaffected skin, in order to compare the presence of mast cells. For aid in the diagnosis, the following stains are recommended to be completed with biopsy: hematoxylin, eosin, toluidine blue, Giemsa, and monoclonal antibodies to tryptase, CD117 and KIT. […] CBC count: In systemic mastocytosis, CBC counts may reveal anemia, thrombocytopenia, thrombocytosis, leukocytosis, and eosinophilia. […] Total tryptase level: Tryptase is a marker of mast cell degranulation released in parallel with histamine. Total tryptase levels in plasma correlate with the density of mast cells in urticaria pigmentosa lesions in adults with systemic mastocytosis. Patients with only cutaneous mastocytosis typically have normal levels of total tryptase. Total tryptase values are recommended by the WHO as a minor criterion for use in the diagnostic evaluation of systemic mastocytosis.

• #24 Diagnostic Workup for Advanced Forms of Mastocytosis – TMS – The Mast Cell Disease Society, IncAccessibilityIncrease TextDecrease TextGrayscaleHigh ContrastNegative ContrastLight BackgroundLinks UnderlineReadable FontReset

  https://tmsforacure.org/expert-information/diagnostic-workup-advanced-forms-mastocytosis/

  Many patients with advanced SM present with abnormal peripheral blood counts. […] An abnormal blood count is also a key finding to detect an AHN and to diagnose SM-AHN. […] Although the presence of the major criterion for diagnosis of SM can be evaluated with a biopsy from any organ involved in disease other than skin (e.g., liver, gastrointestinal tract), bone marrow is the most common site. […] There are many pros of a bone marrow biopsy/aspirate, including providing information on an AHN, rendering differential diagnosis with other possible malignancies, and being easy and safe. […] The most important molecular marker to show monoclonality in SM is the KIT point mutation D816V that can be analyzed in the bone marrow and the peripheral blood. […] In the majority of patients with SM, neoplastic MCs harbor this mutation.

• #25 About Systemic Mastocytosis | Blueprint Medicines

  https://itssmthing.com/about-sm.php

  A tryptase test measures the amount of tryptase (an enzyme released by mast cells) in your blood. […] Genetic tests may include KIT D816V, which is a blood test that measures the genetic mutation (KIT D816V) that is a genetic marker in approximately 95% of SM cases. […] Other tests may include biopsies (skin, bone marrow, liver, spleen, and/or other organs). […] Serum tryptase is useful to evaluate for mast cell activation. Tryptase is a substance that is released from mast cells when the mast cells are stimulated by triggers. The serum tryptase level is used as a diagnostic marker in systemic mastocytosis and may reflect the burden of neoplastic mast cells. […] A KIT D816V blood test may be helpful to aid in the diagnosis of patients who are being evaluated for SM. Since the mutation is found in approximately 95% of SM cases, measurement of this genetic marker can help evaluate for SM. […] The management of SM may require doctors across many specialties, such as allergists/ immunologists, dermatologists, gastroenterologists, or hematologists/oncologists, depending on the symptoms present and type of SM.

• #26 Cutaneous and Systemic Manifestations of Mastocytosis | AAFP

  https://www.aafp.org/pubs/afp/issues/1999/0601/p3047.html

  A liver or bone marrow biopsy in patients with systemic mastocytosis often demonstrates an increase in mast cells. […] Laboratory abnormalities associated with systemic mastocytosis include hypocholesterolemia, thrombocytopenia, eosinophilia and elevation of alkaline phosphatase and liver enzymes. […] A suggested diagnostic work-up for adults with suspected mastocytosis is summarized in Table 4. […] When cutaneous mastocytosis begins in adulthood, a bone marrow biopsy is recommended to exclude the presence of an associated hematologic disease, especially in an elderly patient with systemic symptoms, lymphadenopathy or hepatosplenomegaly. […] Bone marrow biopsy and biochemical tests are required for the diagnosis of systemic mastocytosis in patients without skin involvement.

• #27 Diagnostic Workup for Advanced Forms of Mastocytosis – TMS – The Mast Cell Disease Society, IncAccessibilityIncrease TextDecrease TextGrayscaleHigh ContrastNegative ContrastLight BackgroundLinks UnderlineReadable FontReset

  https://tmsforacure.org/expert-information/diagnostic-workup-advanced-forms-mastocytosis/

  In patients with two or more B-findings the diagnosis of smoldering systemic mastocytosis (SSM) can be established. […] C-findings (one is enough to diagnose aggressive SM) are indicative of ASM or MCL. […] It is of particular importance that organ damage caused by MC infiltration only counts as an SM-related C-finding. […] In case of suspected AHN, further markers and criteria to classify the AHN according to WHO criteria have to be applied to fully diagnose both the SM component and the AHN component of the disease and to identify potential drug targets. […] Elevated serum tryptase is the key finding in patients with SM. […] Moreover, tryptase may serve as a surrogate marker to estimate the aggressiveness of the disease. […] Tryptase measurement is also of importance for the monitoring of SM.

• #28 Mastocytosis Workup: Laboratory Studies, Imaging Studies, Other Tests

  https://emedicine.medscape.com/article/1057932-workup

  In many patients, urticaria pigmentosa (UP) can be diagnosed when history and physical examination findings reveal the characteristic lesions that demonstrate the Darier sign. Usually, a skin biopsy is a necessary confirmatory test, typically through a 3- or 4-mm punch biopsy. It may be helpful to complete two biopsies, one of the suspected lesion and the other of unaffected skin, in order to compare the presence of mast cells. For aid in the diagnosis, the following stains are recommended to be completed with biopsy: hematoxylin, eosin, toluidine blue, Giemsa, and monoclonal antibodies to tryptase, CD117 and KIT. […] CBC count: In systemic mastocytosis, CBC counts may reveal anemia, thrombocytopenia, thrombocytosis, leukocytosis, and eosinophilia. […] Total tryptase level: Tryptase is a marker of mast cell degranulation released in parallel with histamine. Total tryptase levels in plasma correlate with the density of mast cells in urticaria pigmentosa lesions in adults with systemic mastocytosis. Patients with only cutaneous mastocytosis typically have normal levels of total tryptase. Total tryptase values are recommended by the WHO as a minor criterion for use in the diagnostic evaluation of systemic mastocytosis.

• #29 Overview & Diagnosis – TMS – The Mast Cell Disease Society, IncAccessibilityIncrease TextDecrease TextGrayscaleHigh ContrastNegative ContrastLight BackgroundLinks UnderlineReadable FontReset

  https://tmsforacure.org/overview/

  Mastocytosis has been defined in the literature as an abnormal accumulation of mast cells in one or more organ systems. […] The preferred method of diagnosing SM is via bone marrow (BM) biopsy. […] The WHO has established criteria for diagnosing SM, summarized as follows: Major: Multifocal dense infiltrates of mast cells (MCs) (> 15 MCs in aggregate) in tryptase stained biopsy sections of the bone marrow or other extracutaneous organ. […] If at least one major criterion and one minor criterion OR at least three minor criteria are fulfilled, the diagnosis of systemic mastocytosis can be established. […] Recognition by specialist physicians of the importance of mast cell activation in disease led to an international Mast Cell Disorders Working Conference emphasizing this topic in September of 2010.

• #30 Diagnostic Workup for Advanced Forms of Mastocytosis – TMS – The Mast Cell Disease Society, IncAccessibilityIncrease TextDecrease TextGrayscaleHigh ContrastNegative ContrastLight BackgroundLinks UnderlineReadable FontReset

  https://tmsforacure.org/expert-information/diagnostic-workup-advanced-forms-mastocytosis/

  Many patients with advanced SM present with abnormal peripheral blood counts. […] An abnormal blood count is also a key finding to detect an AHN and to diagnose SM-AHN. […] Although the presence of the major criterion for diagnosis of SM can be evaluated with a biopsy from any organ involved in disease other than skin (e.g., liver, gastrointestinal tract), bone marrow is the most common site. […] There are many pros of a bone marrow biopsy/aspirate, including providing information on an AHN, rendering differential diagnosis with other possible malignancies, and being easy and safe. […] The most important molecular marker to show monoclonality in SM is the KIT point mutation D816V that can be analyzed in the bone marrow and the peripheral blood. […] In the majority of patients with SM, neoplastic MCs harbor this mutation.

• #31 Mast Cell Disorders | Choose the Right Test

  https://arupconsult.com/content/mast-cell-disorders

  Recommended laboratory testing in the initial workup of suspected MCDs is similar to testing for many other conditions and includes a CBC with differential, metabolic panel, peripheral smear, and lactate dehydrogenase, liver function, and uric acid tests, as well as testing for mast cell mediators. […] Bone marrow biopsy remains the gold standard for establishing the diagnosis of mastocytosis. […] All individuals suspected of having SM should undergo KIT mutational analysis. […] If a KIT D816V mutation is detected in peripheral blood, a bone marrow biopsy should be performed to evaluate for SM, including the subtype of the disease. […] Laboratory monitoring is recommended every 6-12 months for SM and yearly for indolent SM.

• #32 Systemic Mastocytosis Workup: Approach Considerations, Laboratory Studies, Imaging Studies

  https://emedicine.medscape.com/article/203948-workup

  When GI symptoms are present, perform GI procedures (eg, barium studies, endoscopy) to help confirm the diagnosis. […] Expression of CD25 on mast cells is seen in systemic mastocytosis but is not noted in reactive states of mast cell hyperplasia. […] In 2022, revised criteria for diagnosing systemic mastocytosis were released by the World Health Organization (WHO). […] The WHO classification for diagnosis of systemic mastocytosis requires the presence of a major criterion plus one minor criterion, or the presence of three minor criteria; ICC requires the presence of the major criterion or at least three minor criteria.

• #33 Diagnostic Workup for Advanced Forms of Mastocytosis – TMS – The Mast Cell Disease Society, IncAccessibilityIncrease TextDecrease TextGrayscaleHigh ContrastNegative ContrastLight BackgroundLinks UnderlineReadable FontReset

  https://tmsforacure.org/expert-information/diagnostic-workup-advanced-forms-mastocytosis/

  Many patients with advanced SM present with abnormal peripheral blood counts. […] An abnormal blood count is also a key finding to detect an AHN and to diagnose SM-AHN. […] Although the presence of the major criterion for diagnosis of SM can be evaluated with a biopsy from any organ involved in disease other than skin (e.g., liver, gastrointestinal tract), bone marrow is the most common site. […] There are many pros of a bone marrow biopsy/aspirate, including providing information on an AHN, rendering differential diagnosis with other possible malignancies, and being easy and safe. […] The most important molecular marker to show monoclonality in SM is the KIT point mutation D816V that can be analyzed in the bone marrow and the peripheral blood. […] In the majority of patients with SM, neoplastic MCs harbor this mutation.

• #34 Mast Cell Disorders | Choose the Right Test

  https://arupconsult.com/content/mast-cell-disorders

  Mast cell disorders (MCDs), including mast cell activation syndrome (MCAS) and mastocytosis, are a diverse group of conditions characterized by inappropriate mast cell activation and/or the proliferation and accumulation of abnormal mast cells throughout the body. […] The diagnostic approach depends on the type of MCD but often involves laboratory testing such as serum tryptase measurement and KIT gene mutational analysis on bone marrow and/or peripheral blood. […] Ultrasensitive testing methods such as digital droplet polymerase chain reaction (ddPCR) are the preferred first-line methods for KIT mutational analysis to diagnose mast cell disorders (MCDs), given that these methods are sensitive, highly specific, and can be performed on peripheral blood. […] When evaluating an individual for nonclonal mast cell activation syndrome (NC-MCAS), an increase in the serum level of tryptase above baseline and within a narrow window of time (generally 30 minutes to 2 hours) after a symptomatic episode is the preferred method to provide evidence of mast cell involvement.

• #35 Mastocytosis | MLL

  https://www.mll.com/en/hypereosinophilic-syndromes-and-mastocytosis/mastocytosis

  In the diagnosis of mastocytosis, FISH analysis is usually seen as a complementary method to classical chromosome analysis and is used specifically to answer certain questions. […] A gain-of-function mutation in codon 816 of the receptor tyrosine kinase KIT is detected in 90% of patients with systemic mastocytosis. […] The mutation load of the KIT D816V mutation differs widely between individual patients and subgroups of mastocytosis. […] If systemic mastocytosis is still suspected despite negativity for KIT D816V in peripheral blood, reexamination from bone marrow with expansion to rare other activating KIT mutations is recommended. […] In addition, molecular genetic testing of the TSAB1 gene copy number allows the differential diagnosis of hereditary alpha-tryptasemia (HAT) to be excluded.

• #36 Diagnostic Workup for Advanced Forms of Mastocytosis – TMS – The Mast Cell Disease Society, IncAccessibilityIncrease TextDecrease TextGrayscaleHigh ContrastNegative ContrastLight BackgroundLinks UnderlineReadable FontReset

  https://tmsforacure.org/expert-information/diagnostic-workup-advanced-forms-mastocytosis/

  Diagnostic work-up should include: careful history and physical exam, serum tryptase, bone marrow biopsy and aspirate with appropriate analyses, if serum tryptase is high and/or blood counts are abnormal, molecular testing from bone marrow, abdominal ultrasound, dexa scan and/or other skeletal imaging, endoscopies with biopsies in cases with gastrointestinal symptoms, chest CT, in patients with pulmonary symptoms (very rarely).

• #37 Diagnosis and treatment of systemic mastocytosis in Brazil: Recommendations of a multidisciplinary expert panel | Hematology, Transfusion and Cell Therapy

  http://www.htct.com.br/en-diagnosis-treatment-systemic-mastocytosis-in-articulo-S2531137922000803

  Recommendation: Doppler abdominal ultrasound should be performed for all patients with Systemic Mastocytosis to evaluate hepatomegaly, portal hypertension and ascites (GRADE 3). […] Recommendation: CT scans and MRI should be used to evaluate Systemic Mastocytosis C findings. The FDG-PET/CT scans should not be part of the initial assessment of the most common forms of the disease (GRADE 3). […] Recommendation: The clinical or hybrid Mayo criteria should be used to determine prognosis (GRADE 4). […] Recommendation: The treatment of cutaneous disease should focus on symptomatic relief and trigger avoidance (GRADE 2). […] Recommendation: Antihistamines should be used for the symptomatic treatment (GRADE 2). […] Recommendation: The follow-up in patients with indolent or smouldering Systemic Mastocytosis should include symptomatic management and bone disease measurement (GRADE 3). […] Recommendation: The allogeneic stem cell transplantation should be considered in eligible patients with advanced SM with an estimated survival of fewer than 5 years and/or patients with SM-AHN with hematological neoplasms who have an indication for allogeneic stem cell transplantation (GRADE 4).

• #38 Advanced systemic mastocytosis

  https://www.medicalnewstoday.com/articles/advanced-systemic-mastocytosis

  Some symptoms of advanced systemic mastocytosis include headache, diarrhea, hypotension, and more. […] Doctors may order various tests to diagnose the condition and advise on a suitable treatment plan. […] A doctor may perform several examinations and tests to help diagnose advanced systemic mastocytosis. These include the following: […] Blood test: Complete blood count and elevated tryptase levels can help differentiate the variants of advanced systemic mastocytosis. Tryptase is an enzyme that primarily comes from mast cells. […] Bone marrow biopsy: Using a long needle, the doctor will remove a sample of bone marrow tissue for further testing. […] Imaging tests: Imaging tests, such as ultrasounds, can help the doctor view internal organs and tissues clearly. Additionally, dual-energy X-ray absorptiometry scans can help assess bone density. […] It is best to contact a doctor as soon as there are concerns about advanced systemic mastocytosis. They can order tests to confirm the diagnosis and advise on suitable treatments.

• #39 Systemic mastocytosis – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/systemic-mastocytosis/diagnosis-treatment/drc-20450478

  To diagnose systemic mastocytosis, your doctor will likely start by reviewing your symptoms and discussing your medical history, including medications you’ve taken. He or she can then order tests that look for high levels of mast cells or the substances they release. Evaluation of organs affected by the condition also may be done. […] Tests may include: Blood or urine tests, Bone marrow biopsy, Skin biopsy, Imaging tests such as an X-ray, ultrasound, bone scan and CT scan, Biopsy of organs affected by the disease, such as the liver, Genetic testing. […] Your doctor regularly monitors the status of your condition using blood and urine samples. You may be able to use a special home kit to collect blood and urine samples while you’re experiencing symptoms, which gives your doctor a better picture of how systemic mastocytosis affects your body. Regular bone density measurements can monitor you for problems such as osteoporosis. […] After getting detailed information about the symptoms and your family’s medical history, your doctor may order tests to help with diagnosis and treatment planning.

• #40 Systemic mastocytosis – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/systemic-mastocytosis/diagnosis-treatment/drc-20450478

  To diagnose systemic mastocytosis, your doctor will likely start by reviewing your symptoms and discussing your medical history, including medications you’ve taken. He or she can then order tests that look for high levels of mast cells or the substances they release. Evaluation of organs affected by the condition also may be done. […] Tests may include: Blood or urine tests, Bone marrow biopsy, Skin biopsy, Imaging tests such as an X-ray, ultrasound, bone scan and CT scan, Biopsy of organs affected by the disease, such as the liver, Genetic testing. […] Your doctor regularly monitors the status of your condition using blood and urine samples. You may be able to use a special home kit to collect blood and urine samples while you’re experiencing symptoms, which gives your doctor a better picture of how systemic mastocytosis affects your body. Regular bone density measurements can monitor you for problems such as osteoporosis. […] After getting detailed information about the symptoms and your family’s medical history, your doctor may order tests to help with diagnosis and treatment planning.

• #41 Diagnosis and treatment of systemic mastocytosis in Brazil: Recommendations of a multidisciplinary expert panel | Hematology, Transfusion and Cell Therapy

  http://www.htct.com.br/en-diagnosis-treatment-systemic-mastocytosis-in-articulo-S2531137922000803

  Recommendation: Doppler abdominal ultrasound should be performed for all patients with Systemic Mastocytosis to evaluate hepatomegaly, portal hypertension and ascites (GRADE 3). […] Recommendation: CT scans and MRI should be used to evaluate Systemic Mastocytosis C findings. The FDG-PET/CT scans should not be part of the initial assessment of the most common forms of the disease (GRADE 3). […] Recommendation: The clinical or hybrid Mayo criteria should be used to determine prognosis (GRADE 4). […] Recommendation: The treatment of cutaneous disease should focus on symptomatic relief and trigger avoidance (GRADE 2). […] Recommendation: Antihistamines should be used for the symptomatic treatment (GRADE 2). […] Recommendation: The follow-up in patients with indolent or smouldering Systemic Mastocytosis should include symptomatic management and bone disease measurement (GRADE 3). […] Recommendation: The allogeneic stem cell transplantation should be considered in eligible patients with advanced SM with an estimated survival of fewer than 5 years and/or patients with SM-AHN with hematological neoplasms who have an indication for allogeneic stem cell transplantation (GRADE 4).

• #42 Diagnostic Workup for Advanced Forms of Mastocytosis – TMS – The Mast Cell Disease Society, IncAccessibilityIncrease TextDecrease TextGrayscaleHigh ContrastNegative ContrastLight BackgroundLinks UnderlineReadable FontReset

  https://tmsforacure.org/expert-information/diagnostic-workup-advanced-forms-mastocytosis/

  Diagnostic work-up should include: careful history and physical exam, serum tryptase, bone marrow biopsy and aspirate with appropriate analyses, if serum tryptase is high and/or blood counts are abnormal, molecular testing from bone marrow, abdominal ultrasound, dexa scan and/or other skeletal imaging, endoscopies with biopsies in cases with gastrointestinal symptoms, chest CT, in patients with pulmonary symptoms (very rarely).

• #43 Systemic Mastocytosis Workup: Approach Considerations, Laboratory Studies, Imaging Studies

  https://emedicine.medscape.com/article/203948-workup

  When GI symptoms are present, perform GI procedures (eg, barium studies, endoscopy) to help confirm the diagnosis. […] Expression of CD25 on mast cells is seen in systemic mastocytosis but is not noted in reactive states of mast cell hyperplasia. […] In 2022, revised criteria for diagnosing systemic mastocytosis were released by the World Health Organization (WHO). […] The WHO classification for diagnosis of systemic mastocytosis requires the presence of a major criterion plus one minor criterion, or the presence of three minor criteria; ICC requires the presence of the major criterion or at least three minor criteria.

• #44 Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management – PubMed

  https://pubmed.ncbi.nlm.nih.gov/37309222/

  Systemic mastocytosis (SM) results from clonal proliferation of mast cells (MC) in extracutaneous organs. The major criterion is presence of multifocal MC clusters in the bone marrow and/or extracutaneous organs. Minor diagnostic criteria include elevated serum tryptase level, MC CD25/CD2/CD30 expression, and presence of activating KIT mutations. […] Establishing SM subtype as per the International Consensus Classification/World Health Organization classification systems is an important first step. […] Several risk models are available to help assign prognosis in SM patients.

• #45 Systemic Mastocytosis

  https://www.aaaai.org/conditions-treatments/related-conditions/systemic-mastocytosis

  Most adult patients fit into the indolent systemic mastocytosis category. While they may be symptomatic, indolent systemic mastocytosis patients generally have low morbidity and normal life expectancy not different from their peers. […] Smoldering systemic mastocytosis patients have an inferior survival compared to indolent systemic mastocytosis, but the advanced age of those patients account for most of the difference. […] Indolent systemic mastocytosis patients have a low risk of progression to more severe disease, while the risk of progression to more severe disease is higher for Smoldering systemic mastocytosis patients. […] Aggressive systemic mastocytosis patients have more significant symptoms, including enlarged liver and lymph nodes, as well as blood abnormalities such as anemia and low platelets. […] Patients with systemic mastocytosis with an associated hematologic neoplasm suffer from additional problems caused by the associated blood malignancy. […] Mast cell leukemia is very rare, but comes with a difficult prognosis and shorter life span.

• #46 Diagnostic Workup for Advanced Forms of Mastocytosis – TMS – The Mast Cell Disease Society, IncAccessibilityIncrease TextDecrease TextGrayscaleHigh ContrastNegative ContrastLight BackgroundLinks UnderlineReadable FontReset

  https://tmsforacure.org/expert-information/diagnostic-workup-advanced-forms-mastocytosis/

  In patients with two or more B-findings the diagnosis of smoldering systemic mastocytosis (SSM) can be established. […] C-findings (one is enough to diagnose aggressive SM) are indicative of ASM or MCL. […] It is of particular importance that organ damage caused by MC infiltration only counts as an SM-related C-finding. […] In case of suspected AHN, further markers and criteria to classify the AHN according to WHO criteria have to be applied to fully diagnose both the SM component and the AHN component of the disease and to identify potential drug targets. […] Elevated serum tryptase is the key finding in patients with SM. […] Moreover, tryptase may serve as a surrogate marker to estimate the aggressiveness of the disease. […] Tryptase measurement is also of importance for the monitoring of SM.

• #47 Diagnostic Workup for Advanced Forms of Mastocytosis – TMS – The Mast Cell Disease Society, IncAccessibilityIncrease TextDecrease TextGrayscaleHigh ContrastNegative ContrastLight BackgroundLinks UnderlineReadable FontReset

  https://tmsforacure.org/expert-information/diagnostic-workup-advanced-forms-mastocytosis/

  In patients with two or more B-findings the diagnosis of smoldering systemic mastocytosis (SSM) can be established. […] C-findings (one is enough to diagnose aggressive SM) are indicative of ASM or MCL. […] It is of particular importance that organ damage caused by MC infiltration only counts as an SM-related C-finding. […] In case of suspected AHN, further markers and criteria to classify the AHN according to WHO criteria have to be applied to fully diagnose both the SM component and the AHN component of the disease and to identify potential drug targets. […] Elevated serum tryptase is the key finding in patients with SM. […] Moreover, tryptase may serve as a surrogate marker to estimate the aggressiveness of the disease. […] Tryptase measurement is also of importance for the monitoring of SM.

• #48 Systemic Mastocytosis

  https://www.aaaai.org/conditions-treatments/related-conditions/systemic-mastocytosis

  Most adult patients fit into the indolent systemic mastocytosis category. While they may be symptomatic, indolent systemic mastocytosis patients generally have low morbidity and normal life expectancy not different from their peers. […] Smoldering systemic mastocytosis patients have an inferior survival compared to indolent systemic mastocytosis, but the advanced age of those patients account for most of the difference. […] Indolent systemic mastocytosis patients have a low risk of progression to more severe disease, while the risk of progression to more severe disease is higher for Smoldering systemic mastocytosis patients. […] Aggressive systemic mastocytosis patients have more significant symptoms, including enlarged liver and lymph nodes, as well as blood abnormalities such as anemia and low platelets. […] Patients with systemic mastocytosis with an associated hematologic neoplasm suffer from additional problems caused by the associated blood malignancy. […] Mast cell leukemia is very rare, but comes with a difficult prognosis and shorter life span.

• #49 Systemic Mastocytosis

  https://www.aaaai.org/conditions-treatments/related-conditions/systemic-mastocytosis

  Most adult patients fit into the indolent systemic mastocytosis category. While they may be symptomatic, indolent systemic mastocytosis patients generally have low morbidity and normal life expectancy not different from their peers. […] Smoldering systemic mastocytosis patients have an inferior survival compared to indolent systemic mastocytosis, but the advanced age of those patients account for most of the difference. […] Indolent systemic mastocytosis patients have a low risk of progression to more severe disease, while the risk of progression to more severe disease is higher for Smoldering systemic mastocytosis patients. […] Aggressive systemic mastocytosis patients have more significant symptoms, including enlarged liver and lymph nodes, as well as blood abnormalities such as anemia and low platelets. […] Patients with systemic mastocytosis with an associated hematologic neoplasm suffer from additional problems caused by the associated blood malignancy. […] Mast cell leukemia is very rare, but comes with a difficult prognosis and shorter life span.

• #50 Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment

  https://www.onclive.com/view/advanced-systemic-mastocytosis-expert-insight-into-epidemiology-diagnosis-and-treatment

  Classification of SM can also be a challenge. […] The distinguishing feature of SM is the penetration of MCs into internal organs including the BM at multiple locations within the organ or organs. […] As DeAngelo explained, to diagnose SM according to the WHO, you have to have 1 major and 1 minor or 3 minor criteria. […] The major criterion is multifocal clusters of at least 15 MCs per cluster in 1 or more visceral organs. […] The first is that at least one quarter of MCs in the BM are atypical or spindle-shaped if they are in the visceral organs. […] The second is a KIT point mutation at codon 816 in infiltrated organs. […] The third is exhibition of CD2 and/or CD25 in an infected (but extracutaneous) organ or in the blood. […] The fourth which is not a valid criterion if an unrelated myeloid neoplasm exists is a baseline serum tryptase level above 20 ng/ mL.

• #51 Diagnostic Workup for Advanced Forms of Mastocytosis – TMS – The Mast Cell Disease Society, IncAccessibilityIncrease TextDecrease TextGrayscaleHigh ContrastNegative ContrastLight BackgroundLinks UnderlineReadable FontReset

  https://tmsforacure.org/expert-information/diagnostic-workup-advanced-forms-mastocytosis/

  In patients with two or more B-findings the diagnosis of smoldering systemic mastocytosis (SSM) can be established. […] C-findings (one is enough to diagnose aggressive SM) are indicative of ASM or MCL. […] It is of particular importance that organ damage caused by MC infiltration only counts as an SM-related C-finding. […] In case of suspected AHN, further markers and criteria to classify the AHN according to WHO criteria have to be applied to fully diagnose both the SM component and the AHN component of the disease and to identify potential drug targets. […] Elevated serum tryptase is the key finding in patients with SM. […] Moreover, tryptase may serve as a surrogate marker to estimate the aggressiveness of the disease. […] Tryptase measurement is also of importance for the monitoring of SM.

• #52 Diagnostic Workup for Advanced Forms of Mastocytosis – TMS – The Mast Cell Disease Society, IncAccessibilityIncrease TextDecrease TextGrayscaleHigh ContrastNegative ContrastLight BackgroundLinks UnderlineReadable FontReset

  https://tmsforacure.org/expert-information/diagnostic-workup-advanced-forms-mastocytosis/

  In patients with two or more B-findings the diagnosis of smoldering systemic mastocytosis (SSM) can be established. […] C-findings (one is enough to diagnose aggressive SM) are indicative of ASM or MCL. […] It is of particular importance that organ damage caused by MC infiltration only counts as an SM-related C-finding. […] In case of suspected AHN, further markers and criteria to classify the AHN according to WHO criteria have to be applied to fully diagnose both the SM component and the AHN component of the disease and to identify potential drug targets. […] Elevated serum tryptase is the key finding in patients with SM. […] Moreover, tryptase may serve as a surrogate marker to estimate the aggressiveness of the disease. […] Tryptase measurement is also of importance for the monitoring of SM.

• #53 ASCIA Position Paper – Diagnosis and Investigation of Mast Cell Activation Disorders and Syndrome – Australasian Society of Clinical Immunology and Allergy (ASCIA)

  https://www.allergy.org.au/hp/papers/testing-for-mast-cell-activation-disorders-and-syndrome

  It is agreed that MCAS should be considered a diagnosis of exclusion. […] Therefore for a diagnosis of MCAS, the diagnostic criteria for primary, secondary, and other well-defined idiopathic mast cell activation disorders (MCAD) must be ruled out first, and in addition the criteria for MCAS must be met. […] The key considerations to make a diagnosis of MCAS include severe, recurrent symptoms of mast cell activation (typically anaphylaxis), along with confirmation of mast cell lineage involvement via detection of mast cell mediators. […] In an attempt to provide a consensus on the diagnosis criteria for MCAS, an international consensus group (Valent et. al 2012) proposed the following criteria, where all three criteria should be fulfilled for MCAS to be diagnosed. […] Typical signs and symptoms of mast cell mediator release (affecting at least 2 organ systems)

• #54 ASCIA Position Paper – Diagnosis and Investigation of Mast Cell Activation Disorders and Syndrome – Australasian Society of Clinical Immunology and Allergy (ASCIA)

  https://www.allergy.org.au/hp/papers/testing-for-mast-cell-activation-disorders-and-syndrome

  Mast cell activation syndrome (MCAS) can be defined as a heterogenous group of disorders presenting with episodic symptoms involving multiple systems that are attributable to mast cell mediator release (e.g. flushing, pruritus, wheeze, gastrointestinal symptoms). […] The definition and criteria for MCAS have evolved over time, and there are established diagnostic criteria for MCAS. […] Diagnosis of MCAS based on consensus criteria requires clinical assessment in conjunction with laboratory assessments, of which tryptase is the most accessible and validated test within Australia and New Zealand. […] When a diagnosis of MCAS is being considered it is important to ensure differential diagnoses with overlapping clinical features have been investigated. […] Mast cell activation syndrome (MCAS) has been defined as a heterogenous group of disorders of varied causes that present with episodic symptoms involving multiple systems that are attributable to mast cell mediator release.

• #55 Diagnosis of Mast Cell Diseases

  https://hub.eaaci.org/education_courses/diagnosis-of-mast-cell-diseases/

  The first module focuses on the diagnosis of Mast cell Disorders, with an emphasis on Clonal Mast Cell Disorders: Indolent Systemic Mastocytosis. This module aims to underline the significance of accurate diagnosis in Mast Cell Disorders, particularly in distinguishing between clonal and non-clonal diseases. […] Furthermore, it explains the novel entity Hereditary Alfa Tryptasemia Ipertryptasemia, a new genetic trait crucial to be known given its frequent occurrence in the general populace and its implications for differential diagnosis.

• #56 Mast Cell Disorders | Choose the Right Test

  https://arupconsult.com/content/mast-cell-disorders

  There are multiple options to adjust serum tryptase in hereditary alpha-tryptasemia, including division of the total serum tryptase level by a number equal to one plus the number of copies of TPSAB1 present, in accordance with World Health Organization recommendations. […] Testing should include serum tryptase and peripheral blood testing for the KIT D816V mutation. […] In adults, testing is appropriate in individuals with recurrent anaphylaxis, elevated serum tryptase concentrations, urticaria pigmentosa (mastocytosis of the skin) confirmed by skin biopsy, and other signs and symptoms of mast cell activation. […] The major and minor diagnostic criteria for SM are based on the results of laboratory testing. […] The diagnosis and classification of MCDs is based on the above SM criteria and other findings.

• #57 How to diagnose mast cell activation syndrome: practical considerations – Polish Archives of Internal Medicine

  https://www.mp.pl/paim/issue/article/15212

  Mast cells (MCs) are an important component of the immune system. […] Studies on mastocytosis revealed a subgroup of patients presenting symptoms of increased MC degranulation, defined as mast cell activation syndrome (MCAS). […] The syndrome is diagnosed on the basis of 3 criteria: 1) the presence of typical symptoms; 2) elevation of serum tryptase levels; and 3) response to anti-mediator treatment. […] The diagnosis of MCAS is important especially in patients with anaphylaxis or osteoporosis who require the use of an epinephrine emergency kit and insect venom immunotherapy. […] According to the algorithm proposed by Valent et al, MCAS should be considered when the following 3 criteria are met: 1) Presence of typical and recurrent severe symptoms of excess MC activation (often diagnosed as anaphylaxis affecting at least 2 organs).

• #58 Mastocytosis and Mast Cell Activation Syndrome – Immunology; Allergic Disorders – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/immunology-allergic-disorders/allergic-autoimmune-and-other-hypersensitivity-disorders/mastocytosis-and-mast-cell-activation-syndrome

  Mastocytosis is mast cell proliferation with infiltration of skin or other tissues and organs. Diagnosis is by skin or bone marrow biopsy or both. […] Diagnosis requires bone marrow biopsy and tryptase levels (a marker of mast cell degranulation) in most patients. […] Diagnosis of mastocytosis is confirmed when one major criterion and at least one minor criterion or 3 (of 4) minor criteria are met. […] The diagnosis of mast cell activation syndrome requires meeting all 3 criteria: Symptoms consistent with mast cell degranulation and release of mast cell mediators, Laboratory evidence of an increase in mast cell mediators in the serum or urine such as an increase in serum tryptase during an event of 20% + 2 ng/mL above baseline or an increase in urinary metabolites such as N-methylhistamine, prostaglandin D2, or leukotriene E4, Positive clinical response to anti-mast cell therapy. […] Patients with mast cell activation typically have a normal bone marrow biopsy if it is done.

• #59 Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment

  https://www.onclive.com/view/advanced-systemic-mastocytosis-expert-insight-into-epidemiology-diagnosis-and-treatment

  SYSTEMIC MASTOCYTOSIS (SM) is a rare disease that often first presents on the skin. […] Challenges in identification and diagnosis suggest that SM is underdiagnosed despite its low prevalence. […] Symptoms often vary depending on the location of the MC proliferation, rendering diagnosis and treatment difficult. […] The panelists underscored that the diversity of MCs leads to a wide range of MC activation triggers, a variety of MC functions, and heterogeneous MC disorders, and a host of MC disorder symptoms. […] The diagnosis is further complicated because these 2 diseases and their symptoms mimic so many others that are cardiovascular or have origins in other organ systems, she noted. […] By symptomatology alone, its very confusing to really figure out what the patient is experiencing.

• #60 Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment

  https://www.onclive.com/view/advanced-systemic-mastocytosis-expert-insight-into-epidemiology-diagnosis-and-treatment

  SYSTEMIC MASTOCYTOSIS (SM) is a rare disease that often first presents on the skin. […] Challenges in identification and diagnosis suggest that SM is underdiagnosed despite its low prevalence. […] Symptoms often vary depending on the location of the MC proliferation, rendering diagnosis and treatment difficult. […] The panelists underscored that the diversity of MCs leads to a wide range of MC activation triggers, a variety of MC functions, and heterogeneous MC disorders, and a host of MC disorder symptoms. […] The diagnosis is further complicated because these 2 diseases and their symptoms mimic so many others that are cardiovascular or have origins in other organ systems, she noted. […] By symptomatology alone, its very confusing to really figure out what the patient is experiencing.

• #61 Testing for Systemic Mastocytosis | Blueprint Medicines

  https://itssmthing.com/diagnosis.php

  Getting an SM diagnosis can be a complicated process. Since there are so many different symptoms, it can be tough to connect the pieces of the puzzle. […] Given the rarity of SM, the variety of symptoms are sometimes attributed to other causes before an actual SM diagnosis is made. For example, SM can sometimes be mistaken for a GI disorder or cutaneous mastocytosis. […] Because SM is so rare and awareness of the disease may be low, it often gets misdiagnosed. […] There are several tests that your doctor may use to evaluate for SM. […] This test measures the amount of tryptase (an enzyme that is released by mast cells) in the blood. […] Biopsies are tissue samples taken for closer examination. […] A KIT D816V blood test can help aid in the diagnosis of SM by identifying a genetic mutation that has been found in approximately 95% of patients with SM. […] While one test alone cannot confirm an SM diagnosis, it may help your doctor determine what additional diagnostic testing is needed.

• #62 Reddit – The heart of the internet

  https://www.reddit.com/r/mastocytosis/comments/1ho4eu7/how_did_you_get_a_mastocytosis_diagnosis/

  And please, could someone describe their initial symptoms and a bit about the course of the disease? I visited an immunologist yesterday with a suspected MCAS diagnosis, and she said I might actually have mastocytosis. However, they can only do a tryptase test, and if it’s normal, they can’t do much more than prescribe antihistamines. For those of you diagnosed with mastocytosis, was your tryptase level elevated? If it was higher than normal, by how much? […] I understand that diagnostic options in our country are limited. Are things better in other countries?

• #63 Diagnosis and Medical Testing

  https://www.mastocytosis.ca/en/diagnosis/medical-testing

  Diagnosing these disorders is often a long, complicated process involving many areas of specialty medicine. Many patients suffer declining health for up to 10 years or longer before finally being diagnosed. […] Mastocytosis has a set of standard diagnostic testing. Those with skin or hematological involvement seem to have the best chance of their physicians diagnosing their illness. MCAS and Idiopathic Anaphylaxis involve many tests, most of which may be inconclusive. […] None of the current diagnostic tests are reliable for every patient. Some of these tests often return false-negatives. Some tests return positive results outside the normal range, yet the patient experiences few symptoms and enjoys a normal unrestricted life. Many patients have completely normal test results (eg. tryptase, urine, bone marrow) yet they are disabled by these disorders. The largest discrepancy is reported by patients who test positive for a cutaneous form of Mastocytosis, yet negative test results proving systemic involvement, even though the patients exhibit all the classic symptoms of Systemic Mastocytosis. Physicians and patients worldwide are aware of this.

• #64 Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options | Journal of Hematology & Oncology | Full Text

  https://jhoonline.biomedcentral.com/articles/10.1186/1756-8722-4-10

  The frequency of discovery of associated hematologic neoplasms on marrow biopsy at the time of diagnosis of MCAS remains unclear but in our experience appears very low. […] However, a byproduct of marrow biopsy is that immunohistochemical analysis of the specimen may permit the classification of the mast cell activation disease as SM defined by the WHO criteria or as MCAS (Table 2). […] In this context, it has to be considered that due to the typically patchy distribution of mast cell infiltration in the bones a single marrow biopsy fails to find systemic mastocytosis in the marrow approximately one-sixth of the time [36].

• #65 Diagnosis and Medical Testing

  https://www.mastocytosis.ca/en/diagnosis/medical-testing

  Diagnosing these disorders is often a long, complicated process involving many areas of specialty medicine. Many patients suffer declining health for up to 10 years or longer before finally being diagnosed. […] Mastocytosis has a set of standard diagnostic testing. Those with skin or hematological involvement seem to have the best chance of their physicians diagnosing their illness. MCAS and Idiopathic Anaphylaxis involve many tests, most of which may be inconclusive. […] None of the current diagnostic tests are reliable for every patient. Some of these tests often return false-negatives. Some tests return positive results outside the normal range, yet the patient experiences few symptoms and enjoys a normal unrestricted life. Many patients have completely normal test results (eg. tryptase, urine, bone marrow) yet they are disabled by these disorders. The largest discrepancy is reported by patients who test positive for a cutaneous form of Mastocytosis, yet negative test results proving systemic involvement, even though the patients exhibit all the classic symptoms of Systemic Mastocytosis. Physicians and patients worldwide are aware of this.

• #66 Cutaneous and Systemic Manifestations of Mastocytosis | AAFP

  https://www.aafp.org/pubs/afp/issues/1999/0601/p3047.html

  Mastocytosis is characterized by an excessive number of apparently normal mast cells in the skin and, occasionally, in other organs. […] The diagnosis of mastocytosis is easily missed and often delayed until years after onset, sometimes resulting in a disastrous outcome. […] Recognition of mastocytosis can be difficult, especially in patients who do not have the characteristic skin lesions and Darier’s sign. […] The three criteria to consider for establishing the diagnosis of mastocytosis are as follows: (1) histopathology of a skin lesion, if available; (2) histologic evidence of systemic involvement with or without an underlying hematologic disorder; and (3) biochemical markers of mast cell activity. […] When skin lesions are present, a skin biopsy should be obtained to confirm the diagnosis of mastocytosis, since Darier’s sign is not pathognomonic.

• #67 Multidisciplinary insights: Navigating the challenges of systemic mastocytosis diagnosis and management – touchIMMUNOLOGY

  https://touchimmunologyime.org/mdt-insights-systemic-mastocytosis/

  Multidisciplinary insights: Navigating the challenges of systemic mastocytosis diagnosis and management […] Describe the signs, symptoms and diagnostic pathway for systemic mastocytosis […] Explain how to apply personalized treatment strategies using a multidisciplinary approach to effectively manage systemic mastocytosis […] In this activity, an allergist, dermatologist and haemato-oncologist discuss the diagnosis and management of systemic mastocytosis, including current and emerging treatment options and multidisciplinary approaches to optimize patient care. […] The signs and symptoms of SM are diverse. UP/maculopapular skin lesions are a prominent clinical feature of mastocytosis, and can be found in patients with CM and ISM; they may also occur in patients with ASM. GI symptoms, including nausea, vomiting, abdominal pain and diarrhoea are commonly associated with both non-advanced forms (e.g. ISM) and ASM. Many patients with SM experience episodes of unexplained anaphylaxis.

• #68 Multidisciplinary insights: Navigating the challenges of systemic mastocytosis diagnosis and management – touchIMMUNOLOGY

  https://touchimmunologyime.org/mdt-insights-systemic-mastocytosis/

  Multidisciplinary insights: Navigating the challenges of systemic mastocytosis diagnosis and management […] Describe the signs, symptoms and diagnostic pathway for systemic mastocytosis […] Explain how to apply personalized treatment strategies using a multidisciplinary approach to effectively manage systemic mastocytosis […] In this activity, an allergist, dermatologist and haemato-oncologist discuss the diagnosis and management of systemic mastocytosis, including current and emerging treatment options and multidisciplinary approaches to optimize patient care. […] The signs and symptoms of SM are diverse. UP/maculopapular skin lesions are a prominent clinical feature of mastocytosis, and can be found in patients with CM and ISM; they may also occur in patients with ASM. GI symptoms, including nausea, vomiting, abdominal pain and diarrhoea are commonly associated with both non-advanced forms (e.g. ISM) and ASM. Many patients with SM experience episodes of unexplained anaphylaxis.

• #69 Multidisciplinary insights: Navigating the challenges of systemic mastocytosis diagnosis and management – touchIMMUNOLOGY

  https://touchimmunologyime.org/mdt-insights-systemic-mastocytosis/

  Multidisciplinary insights: Navigating the challenges of systemic mastocytosis diagnosis and management […] Describe the signs, symptoms and diagnostic pathway for systemic mastocytosis […] Explain how to apply personalized treatment strategies using a multidisciplinary approach to effectively manage systemic mastocytosis […] In this activity, an allergist, dermatologist and haemato-oncologist discuss the diagnosis and management of systemic mastocytosis, including current and emerging treatment options and multidisciplinary approaches to optimize patient care. […] The signs and symptoms of SM are diverse. UP/maculopapular skin lesions are a prominent clinical feature of mastocytosis, and can be found in patients with CM and ISM; they may also occur in patients with ASM. GI symptoms, including nausea, vomiting, abdominal pain and diarrhoea are commonly associated with both non-advanced forms (e.g. ISM) and ASM. Many patients with SM experience episodes of unexplained anaphylaxis.

• #70 Multidisciplinary insights: Navigating the challenges of systemic mastocytosis diagnosis and management – touchIMMUNOLOGY

  https://touchimmunologyime.org/mdt-insights-systemic-mastocytosis/

  A 51-item survey of 111 HCPs involved in the management of patients with SM including allergy/immunology specialists and haemato-oncology specialists rated the importance of treatment goals in SM, including differences between the ISM and ASM subtypes. Among HCPs surveyed, the two most important treatment goals identified differed between ISM and ASM. In ISM, better quality of life and improvement of symptoms were the two most important treatment goals; in ASM, improved survival outcomes and reduced organ damage were rated as the two most important. […] Based on the results of the phase II PIONEER trial, avapritinib is currently approved for the treatment of ISM in adults, and patients with moderate-to-severe symptoms inadequately controlled on symptomatic treatment. Avapritinib was superior to placebo in reducing uncontrolled symptoms and mast cell burden in patients with ISM.

• #71 Mast Cell Disorder Treatment – Brigham and Women’s Hospital

  https://www.brighamandwomens.org/medicine/gastroenterology-hepatology-and-endoscopy/advances-newsletters/reducing-gastrointestinal-symptoms-using-mast-cell-disorder-identification-and-treatment

  Brigham and Women’s Hospital (BWH) gastroenterologists Norton J. Greenberger, MD, and Matthew J. Hamilton, MD, specialize in the diagnosis and treatment of mast cell disorders involving the gastrointestinal tract. […] An integral part of the Mastocytosis Center at BWH, they collaborate closely with allergists, immunologists, and pathologists to optimize the care of patients and advance the diagnosis and treatment of mast cell disease. […] Recognizing the constellation of signs and symptoms is extremely important in identifying patients with mast cell disease, particularly mast cell activation syndrome which can masquerade as other conditions like irritable bowel syndrome, said Dr. Greenberger. […] Current testing for patients with mast cell activation syndrome is based on blood and urine tests that have limited accuracy and sensitivity, and the diagnosis is often made only when other disorders have been ruled out, said Dr. Hamilton.

• #72 Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment

  https://www.onclive.com/view/advanced-systemic-mastocytosis-expert-insight-into-epidemiology-diagnosis-and-treatment

  Given the noted difficulties of understanding and identifying the mechanisms of SM, diagnosis is often made differentially, Lugar added, which itself is associated with several challenges. […] We dont have fantastic clinical markers or biomarkers to also guide us for [MC] activation [compared with those for] a true clonal [MC] disorder, Lugar said. […] Genetic testing, such as next-generation sequencing, which DeAngelo referred to as a rapid heme panel, can identify specific mutations (eg, in KIT, SRSF2, TET2, and COX1) that may respond better to certain therapy. […] If a targetable mutation is not identified, Lugar observed, clinicians likely need to experiment with a treatment plan that ameliorates some of the symptoms. […] Treatment options for advanced SM are limited, which likely reflects the diagnostic challenges and lack of clinical biomarkers.

• #73 Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment

  https://www.onclive.com/view/advanced-systemic-mastocytosis-expert-insight-into-epidemiology-diagnosis-and-treatment

  Historically, clinicians have relied on chemotherapy and stem cell transplants to treat aggressive SM, but targeted options are available, and others are in development. […] Midostaurin is an oral multikinase inhibitor that inhibits D816V-mutated KIT. […] It is FDA approved for the treatment of patients with advanced SM. […] For patients with aggressive SM who do not have the D816V c-KIT mutation or whose mutational status is unknown, imatinib is an FDA-approved treatment option. […] In June 2020, the FDA approved avapritinib for the treatment of adult patients with advanced SM, including those with aggressive SM, SM with an associated hematologic neoplasm, and MC leukemia. […] As testing methods and treatment options expand, the rarity and complexity of SM will continue to present significant challenges regarding identification and management. […] Given the importance of making a definitive diagnosis, both from a molecular and a histopathologic perspective, DeAngelo believes that clinicians and pathologists must work together to ensure diagnostic accuracy.

• #74 Mast Cell Disorder Treatment – Brigham and Women’s Hospital

  https://www.brighamandwomens.org/medicine/gastroenterology-hepatology-and-endoscopy/advances-newsletters/reducing-gastrointestinal-symptoms-using-mast-cell-disorder-identification-and-treatment

  In conjunction with pathologists in the Center, Dr. Hamilton has established new methods of diagnosing mast cell disorders from gastrointestinal biopsies. […] The team determined that a diagnosis of systemic mastocytosis, traditionally made through bone marrow biopsy, may be achieved from gastrointestinal biopsies using specialized immunohistochemistry. […] They are researching similar markers in MCAS and are studying how the phenotype of mast cells in gastrointestinal tissue can be used to determine the relative state of mast cell activation and aid in diagnosis.

• #75 Systemic mastocytosis – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/systemic-mastocytosis/diagnosis-treatment/drc-20450478

  To diagnose systemic mastocytosis, your doctor will likely start by reviewing your symptoms and discussing your medical history, including medications you’ve taken. He or she can then order tests that look for high levels of mast cells or the substances they release. Evaluation of organs affected by the condition also may be done. […] Tests may include: Blood or urine tests, Bone marrow biopsy, Skin biopsy, Imaging tests such as an X-ray, ultrasound, bone scan and CT scan, Biopsy of organs affected by the disease, such as the liver, Genetic testing. […] Your doctor regularly monitors the status of your condition using blood and urine samples. You may be able to use a special home kit to collect blood and urine samples while you’re experiencing symptoms, which gives your doctor a better picture of how systemic mastocytosis affects your body. Regular bone density measurements can monitor you for problems such as osteoporosis. […] After getting detailed information about the symptoms and your family’s medical history, your doctor may order tests to help with diagnosis and treatment planning.

• #76 Systemic mastocytosis – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/systemic-mastocytosis/diagnosis-treatment/drc-20450478

  To diagnose systemic mastocytosis, your doctor will likely start by reviewing your symptoms and discussing your medical history, including medications you’ve taken. He or she can then order tests that look for high levels of mast cells or the substances they release. Evaluation of organs affected by the condition also may be done. […] Tests may include: Blood or urine tests, Bone marrow biopsy, Skin biopsy, Imaging tests such as an X-ray, ultrasound, bone scan and CT scan, Biopsy of organs affected by the disease, such as the liver, Genetic testing. […] Your doctor regularly monitors the status of your condition using blood and urine samples. You may be able to use a special home kit to collect blood and urine samples while you’re experiencing symptoms, which gives your doctor a better picture of how systemic mastocytosis affects your body. Regular bone density measurements can monitor you for problems such as osteoporosis. […] After getting detailed information about the symptoms and your family’s medical history, your doctor may order tests to help with diagnosis and treatment planning.

• #77 Diagnosis and treatment of systemic mastocytosis in Brazil: Recommendations of a multidisciplinary expert panel | Hematology, Transfusion and Cell Therapy

  http://www.htct.com.br/en-diagnosis-treatment-systemic-mastocytosis-in-articulo-S2531137922000803

  The presence of atypical morphology in more than 25% of the MCs, including spindle-shaped MCs, is considered a minor criterion. […] The sensitivity of the KIT mutation testing for the SM diagnosis may be enhanced by enriching the sample for abnormal MCs by using laser capture microdissection, magnetic bead-based, FACS-based cell sorting and other techniques with higher sensitivity. […] Suggestion: New or modified diagnostic criteria with higher sensitivity should be included in future revisions of the WHO criteria to diagnose Systemic Mastocytosis (GRADE 3). […] Recommendation: Tryptase level measurements are necessary for the Systemic Mastocytosis diagnosis and follow-up (GRADE 2) at least once a year (GRADE 5). […] Recommendation: The D816V KIT mutations should be investigated in all patients with Systemic Mastocytosis.

• #78 Mast Cell Disorders | Choose the Right Test

  https://arupconsult.com/content/mast-cell-disorders

  Recommended laboratory testing in the initial workup of suspected MCDs is similar to testing for many other conditions and includes a CBC with differential, metabolic panel, peripheral smear, and lactate dehydrogenase, liver function, and uric acid tests, as well as testing for mast cell mediators. […] Bone marrow biopsy remains the gold standard for establishing the diagnosis of mastocytosis. […] All individuals suspected of having SM should undergo KIT mutational analysis. […] If a KIT D816V mutation is detected in peripheral blood, a bone marrow biopsy should be performed to evaluate for SM, including the subtype of the disease. […] Laboratory monitoring is recommended every 6-12 months for SM and yearly for indolent SM.

• #79 Systemic mastocytosis – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/systemic-mastocytosis/diagnosis-treatment/drc-20450478

  To diagnose systemic mastocytosis, your doctor will likely start by reviewing your symptoms and discussing your medical history, including medications you’ve taken. He or she can then order tests that look for high levels of mast cells or the substances they release. Evaluation of organs affected by the condition also may be done. […] Tests may include: Blood or urine tests, Bone marrow biopsy, Skin biopsy, Imaging tests such as an X-ray, ultrasound, bone scan and CT scan, Biopsy of organs affected by the disease, such as the liver, Genetic testing. […] Your doctor regularly monitors the status of your condition using blood and urine samples. You may be able to use a special home kit to collect blood and urine samples while you’re experiencing symptoms, which gives your doctor a better picture of how systemic mastocytosis affects your body. Regular bone density measurements can monitor you for problems such as osteoporosis. […] After getting detailed information about the symptoms and your family’s medical history, your doctor may order tests to help with diagnosis and treatment planning.

• #80 Diagnosis and treatment of systemic mastocytosis in Brazil: Recommendations of a multidisciplinary expert panel | Hematology, Transfusion and Cell Therapy

  http://www.htct.com.br/en-diagnosis-treatment-systemic-mastocytosis-in-articulo-S2531137922000803

  Recommendation: Doppler abdominal ultrasound should be performed for all patients with Systemic Mastocytosis to evaluate hepatomegaly, portal hypertension and ascites (GRADE 3). […] Recommendation: CT scans and MRI should be used to evaluate Systemic Mastocytosis C findings. The FDG-PET/CT scans should not be part of the initial assessment of the most common forms of the disease (GRADE 3). […] Recommendation: The clinical or hybrid Mayo criteria should be used to determine prognosis (GRADE 4). […] Recommendation: The treatment of cutaneous disease should focus on symptomatic relief and trigger avoidance (GRADE 2). […] Recommendation: Antihistamines should be used for the symptomatic treatment (GRADE 2). […] Recommendation: The follow-up in patients with indolent or smouldering Systemic Mastocytosis should include symptomatic management and bone disease measurement (GRADE 3). […] Recommendation: The allogeneic stem cell transplantation should be considered in eligible patients with advanced SM with an estimated survival of fewer than 5 years and/or patients with SM-AHN with hematological neoplasms who have an indication for allogeneic stem cell transplantation (GRADE 4).

• #81 Diagnosing MCAS | Mast Cell Action

  https://www.mastcellaction.org/diagnosing-mcas

  In this article, the diagnostic criteria are reviewed and other diseases in the differential diagnosis outlined. […] Another step in the diagnosis of MCAS is often referred to as a test of treatment. […] Not everyone with MCAS will respond to the same medicines, so finding one that works can be a process of trial and error. […] Ideally, the previous steps are combined with a biochemical assessment to show evidence of elevated mediator release from mast cells. […] No single mediator test is definitive; a positive result is not to say that a person certainly has MCAS and, similarly, a negative result is not sufficient to rule out an MCAS diagnosis. […] However, when considered alongside other diagnostic evidence, these mediator tests can provide reasonable confidence in a diagnosis. […] Finally, it is important to discount other potential diagnoses and/or determine whether an individual has multiple conditions (with or without MCAS).

• #82 Diagnosis and treatment of systemic mastocytosis in Brazil: Recommendations of a multidisciplinary expert panel | Hematology, Transfusion and Cell Therapy

  http://www.htct.com.br/en-diagnosis-treatment-systemic-mastocytosis-in-articulo-S2531137922000803

  Recommendation: Doppler abdominal ultrasound should be performed for all patients with Systemic Mastocytosis to evaluate hepatomegaly, portal hypertension and ascites (GRADE 3). […] Recommendation: CT scans and MRI should be used to evaluate Systemic Mastocytosis C findings. The FDG-PET/CT scans should not be part of the initial assessment of the most common forms of the disease (GRADE 3). […] Recommendation: The clinical or hybrid Mayo criteria should be used to determine prognosis (GRADE 4). […] Recommendation: The treatment of cutaneous disease should focus on symptomatic relief and trigger avoidance (GRADE 2). […] Recommendation: Antihistamines should be used for the symptomatic treatment (GRADE 2). […] Recommendation: The follow-up in patients with indolent or smouldering Systemic Mastocytosis should include symptomatic management and bone disease measurement (GRADE 3). […] Recommendation: The allogeneic stem cell transplantation should be considered in eligible patients with advanced SM with an estimated survival of fewer than 5 years and/or patients with SM-AHN with hematological neoplasms who have an indication for allogeneic stem cell transplantation (GRADE 4).

• #83 Diagnosis and treatment of systemic mastocytosis in Brazil: Recommendations of a multidisciplinary expert panel | Hematology, Transfusion and Cell Therapy

  http://www.htct.com.br/en-diagnosis-treatment-systemic-mastocytosis-in-articulo-S2531137922000803

  The presence of atypical morphology in more than 25% of the MCs, including spindle-shaped MCs, is considered a minor criterion. […] The sensitivity of the KIT mutation testing for the SM diagnosis may be enhanced by enriching the sample for abnormal MCs by using laser capture microdissection, magnetic bead-based, FACS-based cell sorting and other techniques with higher sensitivity. […] Suggestion: New or modified diagnostic criteria with higher sensitivity should be included in future revisions of the WHO criteria to diagnose Systemic Mastocytosis (GRADE 3). […] Recommendation: Tryptase level measurements are necessary for the Systemic Mastocytosis diagnosis and follow-up (GRADE 2) at least once a year (GRADE 5). […] Recommendation: The D816V KIT mutations should be investigated in all patients with Systemic Mastocytosis.

• #84 Diagnosis and treatment of systemic mastocytosis in Brazil: Recommendations of a multidisciplinary expert panel | Hematology, Transfusion and Cell Therapy

  http://www.htct.com.br/en-diagnosis-treatment-systemic-mastocytosis-in-articulo-S2531137922000803

  The presence of atypical morphology in more than 25% of the MCs, including spindle-shaped MCs, is considered a minor criterion. […] The sensitivity of the KIT mutation testing for the SM diagnosis may be enhanced by enriching the sample for abnormal MCs by using laser capture microdissection, magnetic bead-based, FACS-based cell sorting and other techniques with higher sensitivity. […] Suggestion: New or modified diagnostic criteria with higher sensitivity should be included in future revisions of the WHO criteria to diagnose Systemic Mastocytosis (GRADE 3). […] Recommendation: Tryptase level measurements are necessary for the Systemic Mastocytosis diagnosis and follow-up (GRADE 2) at least once a year (GRADE 5). […] Recommendation: The D816V KIT mutations should be investigated in all patients with Systemic Mastocytosis.

• #85 Mast cell activation disease diagnosis can reveal PI | Immune Deficiency Foundation

  https://primaryimmune.org/resources/news-articles/mast-cell-activation-disease-diagnosis-can-reveal-pi

  The gold standard for diagnosing misbehaving mast cells is the tissue. […] Proper diagnosis allows greater specificity in treatment, said Maitland. […] Once you’ve identified someone that has MCAS or MCAD and you’ve identified why, such that they have, for instance, positive allergy tests or they’re dealing with recurrent infections, or they have an immunodeficiency, depending on what is tickling the mast cells to release those chemicals inappropriately, you then can tailor the therapies based on the positive testing, she said. […] We need more data and validated tests to identify whether or not somebody’s mast cells are misbehaving.

• #86 Decoding Mastocytosis: A Dive into Diagnostic Pathways – BLDG Active

  https://www.bldgactive.com/blog-decoding-mastocytosis-a-dive-into-diagnostic-pathways-2/?srsltid=AfmBOoo6MCJCOSKcWY5gECGBspNsECM0SEAUrw_XskmpRON0BBnKHeRa

  Mastocytosis is a complex condition that often presents with a wide range of symptoms, making diagnosis a challenging task. […] The journey to diagnose mastocytosis typically begins with a thorough clinical evaluation. Patients may present with symptoms such as skin rashes, gastrointestinal issues, or even anaphylactic reactions. […] To confirm suspicions of mastocytosis, blood tests play a pivotal role. The focus shifts to identifying specific biomarkers, such as elevated serum tryptase levels. […] When blood tests indicate a potential mastocytosis diagnosis, a tissue biopsy becomes the next critical step. Skin biopsies are the most common method used, as mast cells often accumulate in the skin. […] In certain cases, genetic testing can provide further insights. Mutations in genes like KIT are associated with mastocytosis, and identifying these mutations can aid in diagnosis and treatment planning. […] In conclusion, “Decoding Mastocytosis: A Dive into Diagnostic Pathways” has unveiled the intricate steps involved in diagnosing this rare but impactful condition.

• #87 Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment

  https://www.onclive.com/view/advanced-systemic-mastocytosis-expert-insight-into-epidemiology-diagnosis-and-treatment

  Given the noted difficulties of understanding and identifying the mechanisms of SM, diagnosis is often made differentially, Lugar added, which itself is associated with several challenges. […] We dont have fantastic clinical markers or biomarkers to also guide us for [MC] activation [compared with those for] a true clonal [MC] disorder, Lugar said. […] Genetic testing, such as next-generation sequencing, which DeAngelo referred to as a rapid heme panel, can identify specific mutations (eg, in KIT, SRSF2, TET2, and COX1) that may respond better to certain therapy. […] If a targetable mutation is not identified, Lugar observed, clinicians likely need to experiment with a treatment plan that ameliorates some of the symptoms. […] Treatment options for advanced SM are limited, which likely reflects the diagnostic challenges and lack of clinical biomarkers.

• #88 Diagnosis and treatment of systemic mastocytosis in Brazil: Recommendations of a multidisciplinary expert panel | Hematology, Transfusion and Cell Therapy

  http://www.htct.com.br/en-diagnosis-treatment-systemic-mastocytosis-in-articulo-S2531137922000803

  The presence of atypical morphology in more than 25% of the MCs, including spindle-shaped MCs, is considered a minor criterion. […] The sensitivity of the KIT mutation testing for the SM diagnosis may be enhanced by enriching the sample for abnormal MCs by using laser capture microdissection, magnetic bead-based, FACS-based cell sorting and other techniques with higher sensitivity. […] Suggestion: New or modified diagnostic criteria with higher sensitivity should be included in future revisions of the WHO criteria to diagnose Systemic Mastocytosis (GRADE 3). […] Recommendation: Tryptase level measurements are necessary for the Systemic Mastocytosis diagnosis and follow-up (GRADE 2) at least once a year (GRADE 5). […] Recommendation: The D816V KIT mutations should be investigated in all patients with Systemic Mastocytosis.

• #89 Mastocytosis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3863935/

  Mastocytosis is a disorder of abnormal mast cell proliferation with clinical features that include flushing, pruritus, abdominal pain, diarrhea, hypotension, syncope and musculoskeletal pain. […] This article encapsulates the etiology and pathogenesis of mastocytosis with an overview of the clinical features and the approach to diagnosis, evaluation and therapy in adults and pediatric patients. […] Mastocytosis is diagnosed on the basis of history, clinical manifestations, histopathology and laboratory evaluation. It is then classified as to variant based on WHO criteria. […] The diagnosis of cutaneous mastocytosis based on macroscopic appearance is confirmed with a lesional skin biopsy demonstrating characteristic skin histopathology. […] The current approach to the work-up of a patient for systemic mastocytosis consists of a medical evaluation including a bone marrow biopsy and aspirate, a serum tryptase level, and an analysis for an activating mutation in KIT, preferably on bone marrow mononuclear cells.

• #90 Systemic mastocytosis – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/systemic-mastocytosis/diagnosis-treatment/drc-20450478

  To diagnose systemic mastocytosis, your doctor will likely start by reviewing your symptoms and discussing your medical history, including medications you’ve taken. He or she can then order tests that look for high levels of mast cells or the substances they release. Evaluation of organs affected by the condition also may be done. […] Tests may include: Blood or urine tests, Bone marrow biopsy, Skin biopsy, Imaging tests such as an X-ray, ultrasound, bone scan and CT scan, Biopsy of organs affected by the disease, such as the liver, Genetic testing. […] Your doctor regularly monitors the status of your condition using blood and urine samples. You may be able to use a special home kit to collect blood and urine samples while you’re experiencing symptoms, which gives your doctor a better picture of how systemic mastocytosis affects your body. Regular bone density measurements can monitor you for problems such as osteoporosis. […] After getting detailed information about the symptoms and your family’s medical history, your doctor may order tests to help with diagnosis and treatment planning.

• #91 Systemic Mastocytosis Workup: Approach Considerations, Laboratory Studies, Imaging Studies

  https://emedicine.medscape.com/article/203948-workup

  Blood studies used in the diagnosis of systemic mastocytosis include the following: […] The World Health Organization has established diagnostic and classification criteria for systemic mastocytosis. […] Total serum tryptase levels of 20 ng/mL or higher in a baseline serum sample that is associated with a ratio of total to beta-tryptase ratio greater than 20:1 is suggestive of systemic mastocytosis. […] However, a normal serum tryptase level does not exclude the diagnosis of systemic mastocytosis. […] Cytogenetic data indicate that about 20% of patients with systemic mastocytosis have an abnormal karyotype. […] Molecular testing for KIT D816V mutation is universally positive, whereas JAK2 V617F is rarely positive (4%). […] Bone marrow aspiration and biopsy is essential for the diagnosis of systemic mastocytosis.

• #92

  https://www.nhs.uk/conditions/mastocytosis/

  A physical examination of the skin is the first stage in diagnosing cutaneous mastocytosis. […] It’s usually possible to confirm a diagnosis by carrying out a biopsy, where a small skin sample is taken and checked for mast cells. […] A diagnosis of systemic mastocytosis is usually made by finding typical changes on a bone marrow biopsy.

• #93 Diagnostic Workup for Advanced Forms of Mastocytosis – TMS – The Mast Cell Disease Society, IncAccessibilityIncrease TextDecrease TextGrayscaleHigh ContrastNegative ContrastLight BackgroundLinks UnderlineReadable FontReset

  https://tmsforacure.org/expert-information/diagnostic-workup-advanced-forms-mastocytosis/

  Many patients with advanced SM present with abnormal peripheral blood counts. […] An abnormal blood count is also a key finding to detect an AHN and to diagnose SM-AHN. […] Although the presence of the major criterion for diagnosis of SM can be evaluated with a biopsy from any organ involved in disease other than skin (e.g., liver, gastrointestinal tract), bone marrow is the most common site. […] There are many pros of a bone marrow biopsy/aspirate, including providing information on an AHN, rendering differential diagnosis with other possible malignancies, and being easy and safe. […] The most important molecular marker to show monoclonality in SM is the KIT point mutation D816V that can be analyzed in the bone marrow and the peripheral blood. […] In the majority of patients with SM, neoplastic MCs harbor this mutation.

• #94 Systemic mastocytosis – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/systemic-mastocytosis/diagnosis-treatment/drc-20450478

  To diagnose systemic mastocytosis, your doctor will likely start by reviewing your symptoms and discussing your medical history, including medications you’ve taken. He or she can then order tests that look for high levels of mast cells or the substances they release. Evaluation of organs affected by the condition also may be done. […] Tests may include: Blood or urine tests, Bone marrow biopsy, Skin biopsy, Imaging tests such as an X-ray, ultrasound, bone scan and CT scan, Biopsy of organs affected by the disease, such as the liver, Genetic testing. […] Your doctor regularly monitors the status of your condition using blood and urine samples. You may be able to use a special home kit to collect blood and urine samples while you’re experiencing symptoms, which gives your doctor a better picture of how systemic mastocytosis affects your body. Regular bone density measurements can monitor you for problems such as osteoporosis. […] After getting detailed information about the symptoms and your family’s medical history, your doctor may order tests to help with diagnosis and treatment planning.

• #95 Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management – PubMed

  https://pubmed.ncbi.nlm.nih.gov/37309222/

  Systemic mastocytosis (SM) results from clonal proliferation of mast cells (MC) in extracutaneous organs. The major criterion is presence of multifocal MC clusters in the bone marrow and/or extracutaneous organs. Minor diagnostic criteria include elevated serum tryptase level, MC CD25/CD2/CD30 expression, and presence of activating KIT mutations. […] Establishing SM subtype as per the International Consensus Classification/World Health Organization classification systems is an important first step. […] Several risk models are available to help assign prognosis in SM patients.

• #96 Multidisciplinary insights: Navigating the challenges of systemic mastocytosis diagnosis and management – touchIMMUNOLOGY

  https://touchimmunologyime.org/mdt-insights-systemic-mastocytosis/

  Current ICC/WHO guidelines outline the role of B and C findings in the classification of SM subtypes. The presence of C findings support the diagnosis of ASM, while evaluation of B findings can distinguish between SSM and ISM, and help identify BMM. The presence of two or more B findings in the absence of C findings suggests a diagnosis of SSM. […] As a complex, multisystem disease with a varied clinical course, SM requires a multidisciplinary approach. Patients with SM may need psychological or psychiatric support to adjust to their diagnosis. Real-world analysis of US healthcare records of patients with SM (N=8,710) showed that 3.9% of patients with ISM included in the analysis progressed to advanced disease over the 24 month timeframe evaluated. […] Warnings and precautions for avapritinib outlined in prescribing guidance include intracranial haemorrhage and cognitive effects; therefore, in patients with ASM, a platelet count must be performed prior to initiating avapritinib. Avapritinib is not recommended for the treatment of patients with ASM with platelet counts 50 x 109/L; in the United States this limitation of use also extends to patients with ISM.

• #97 Systemic Mastocytosis

  https://www.aaaai.org/conditions-treatments/related-conditions/systemic-mastocytosis

  Mastocytosis is diagnosed by sampling the tissues where there is an abundance by using biopsies, measuring mast cell mediators in blood and urine, blood counts, liver function studies and genetic tests. […] Thus, in adults it is important to look for possible systemic mastocytosis using biopsies of organs in addition to the skin. A bone marrow biopsy is typically used because mast cell precursors originate in the bone marrow before migrating to other organs to mature and are more abundant there. […] The diagnosis of systemic mastocytosis is determined by criteria established by the World Health Organization consensus group and requires meeting the major criterion plus one minor criterion or, alternatively, three of the minor criteria. […] The subgroups are listed here, with indolent systemic mastocytosis being the most frequent, and the other subgroups in order of increasing aggressiveness: Indolent systemic mastocytosis Smoldering systemic mastocytosis Aggressive systemic mastocytosis Systemic mastocytosis with an associated hematologic neoplasm Mast cell leukemia.

• #98 Diagnostic Workup for Advanced Forms of Mastocytosis – TMS – The Mast Cell Disease Society, IncAccessibilityIncrease TextDecrease TextGrayscaleHigh ContrastNegative ContrastLight BackgroundLinks UnderlineReadable FontReset

  https://tmsforacure.org/expert-information/diagnostic-workup-advanced-forms-mastocytosis/

  In patients with two or more B-findings the diagnosis of smoldering systemic mastocytosis (SSM) can be established. […] C-findings (one is enough to diagnose aggressive SM) are indicative of ASM or MCL. […] It is of particular importance that organ damage caused by MC infiltration only counts as an SM-related C-finding. […] In case of suspected AHN, further markers and criteria to classify the AHN according to WHO criteria have to be applied to fully diagnose both the SM component and the AHN component of the disease and to identify potential drug targets. […] Elevated serum tryptase is the key finding in patients with SM. […] Moreover, tryptase may serve as a surrogate marker to estimate the aggressiveness of the disease. […] Tryptase measurement is also of importance for the monitoring of SM.

• #99 Mastocytosis – Wikipedia

  https://en.wikipedia.org/wiki/Mastocytosis

  Mastocytosis, a type of mast cell disease, is a rare disorder affecting both children and adults caused by the accumulation of functionally defective mast cells (also called mastocytes) and CD34+ mast cell precursors. […] Diagnosis of urticaria pigmentosa (cutaneous mastocytosis, see above) can often be done by seeing the characteristic lesions that are dark brown and fixed. A small skin sample (biopsy) may help confirm the diagnosis. […] In case of suspicion of systemic disease the level of serum tryptase in the blood can be of help. If the base level of s-tryptase is elevated, this implies that the mastocytosis can be systemic. In cases of suspicion of SM help can also be drawn from analysis of mutation in KIT(D816V) in peripheral blood using sensitive PCR-technology. […] To set the diagnosis of systemic mastocytosis, certain criteria must be met. Either one major + one minor criterion or three minor criteria has to be fulfilled. […] Dense infiltrates of 15 mast cells in the bone marrow or an extracutaneous organ. […] Aberrant phenotype on the mast cells (pos. for CD2 and/or CD25). […] Aberrant mast cell morphology (spindle-shaped). […] Finding of mutation in KIT(D816V). […] S-tryptase 20 ng/ml.

Zobacz więcej